BR0212329A - Métodos para tratar doença pulmonar - Google Patents

Métodos para tratar doença pulmonar

Info

Publication number
BR0212329A
BR0212329A BR0212329-0A BR0212329A BR0212329A BR 0212329 A BR0212329 A BR 0212329A BR 0212329 A BR0212329 A BR 0212329A BR 0212329 A BR0212329 A BR 0212329A
Authority
BR
Brazil
Prior art keywords
methods
lung disease
treat lung
pulmonary
hemodynamics
Prior art date
Application number
BR0212329-0A
Other languages
English (en)
Inventor
Glenn J Smits
Francis G Spinale
Original Assignee
Biogen Idec Inc
Musc Found For Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Musc Found For Res Dev filed Critical Biogen Idec Inc
Publication of BR0212329A publication Critical patent/BR0212329A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODOS PARA TRATAR DOENçA PULMONAR". Métodos úteis para reduzir a vasoconstrição pulmonar ou melhorar as hemodinâmicas pulmonares em um paciente são descritos. Mais particularmente, esta invenção refere-se à administração de antagonistas de receptor de adenosina A, para reduzir a vasoconstrição pulmonar e melhorar as hemodinâmicas pulmonares.
BR0212329-0A 2001-09-06 2002-09-06 Métodos para tratar doença pulmonar BR0212329A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31790801P 2001-09-06 2001-09-06
PCT/US2002/028580 WO2003022284A1 (en) 2001-09-06 2002-09-06 Methods of treating pulmonary disease

Publications (1)

Publication Number Publication Date
BR0212329A true BR0212329A (pt) 2004-09-21

Family

ID=23235775

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212329-0A BR0212329A (pt) 2001-09-06 2002-09-06 Métodos para tratar doença pulmonar

Country Status (20)

Country Link
US (1) US20040259889A1 (pt)
EP (1) EP1429775A4 (pt)
JP (2) JP4388373B2 (pt)
KR (1) KR100979738B1 (pt)
CN (1) CN1564688A (pt)
AU (1) AU2002341618B2 (pt)
BR (1) BR0212329A (pt)
CA (1) CA2459533A1 (pt)
EA (1) EA014684B1 (pt)
GE (1) GEP20074132B (pt)
HU (1) HUP0401805A3 (pt)
IL (1) IL160715A0 (pt)
IS (1) IS7163A (pt)
MX (1) MXPA04002135A (pt)
NZ (1) NZ532083A (pt)
PL (1) PL368935A1 (pt)
UA (1) UA80258C2 (pt)
WO (1) WO2003022284A1 (pt)
YU (1) YU20104A (pt)
ZA (1) ZA200401765B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA84404C2 (ru) * 2002-06-12 2008-10-27 Байоджен Айдек Ма Инк. Способ лечения ишемического реперфузионного повреждения с помощью антагонистов рецептора аденозина
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
CN1859913A (zh) * 2003-04-25 2006-11-08 美国诺华卡迪亚公司 改善肾功能损伤个体多尿症的方法
EP1636229A4 (en) * 2003-06-06 2008-07-30 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
CA2648281A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
US7511050B2 (en) 2006-06-23 2009-03-31 Incyte Corporation Purinone derivatives as HM74A agonists
AR061626A1 (es) 2006-06-23 2008-09-10 Incyte Corp Derivados de purinona como agonistas de hm74a
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2009055021A1 (en) * 2007-10-26 2009-04-30 New York University School Of Medicine Methods and compositions for treating hepatic diseases
US20090228097A1 (en) * 2008-03-07 2009-09-10 Abbott Cardiovascular Systems Inc. A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device
WO2009152458A1 (en) * 2008-06-13 2009-12-17 Biogen Idec Ma Inc. Liquid formulation suitable for infusion comprising an adenosine receptor antagonist for treating heart failure and renal insufficiency.
KR20130088834A (ko) * 2010-06-30 2013-08-08 길리애드 사이언시즈, 인코포레이티드 폐 고혈압의 치료를 위한 ａ２ｂ 아데노신 수용체 길항제의 용도
BR112015021386A2 (pt) * 2013-03-14 2017-07-18 Bristol Myers Squibb Co moduladores de ácido biciclo [2.2.2] gpr120
AU2019205661B2 (en) 2018-01-04 2022-06-30 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208240A (en) * 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents
TW252044B (pt) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
SI0812844T1 (en) * 1996-06-07 2003-02-28 Hoechst Aktiengesellschaft Use of theophyllin derivatives for the treatment and prophylaxis fo shock conditions, novel xanthine compounds and processes for the production thereof
GB9723553D0 (en) * 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
ZA9810766B (en) * 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity
CA2312867A1 (en) * 1998-01-09 1999-07-15 The Trustees Of The University Of Pennsylvania Compositions and methods for use in ischemia-reperfusion and endotoxin-related tissue injury
EP0970696A1 (en) * 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Combination of loop diuretics with adenosine A1-receptor antagonists
NZ527917A (en) * 1999-11-12 2005-03-24 Biogen Inc Polycycoalkylpurines as adenosine receptor antagonists
ES2269217T3 (es) * 1999-12-02 2007-04-01 Osi Pharmaceuticals, Inc. Compuestos especificos para los receptores a1, a2a y a3 de adenosina y sus usos.

Also Published As

Publication number Publication date
JP2005501915A (ja) 2005-01-20
GEP20074132B (en) 2007-06-25
EP1429775A4 (en) 2007-04-11
JP2009209156A (ja) 2009-09-17
ZA200401765B (en) 2005-04-05
HUP0401805A3 (en) 2007-05-02
IS7163A (is) 2004-02-26
EP1429775A1 (en) 2004-06-23
CA2459533A1 (en) 2003-03-20
WO2003022284A1 (en) 2003-03-20
AU2002341618B2 (en) 2008-06-26
EA200400399A1 (ru) 2004-08-26
MXPA04002135A (es) 2005-03-07
KR20040040457A (ko) 2004-05-12
YU20104A (sh) 2006-08-17
EA014684B1 (ru) 2010-12-30
KR100979738B1 (ko) 2010-09-09
JP4388373B2 (ja) 2009-12-24
IL160715A0 (en) 2004-08-31
UA80258C2 (en) 2007-09-10
PL368935A1 (en) 2005-04-04
CN1564688A (zh) 2005-01-12
HUP0401805A2 (hu) 2004-12-28
US20040259889A1 (en) 2004-12-23
NZ532083A (en) 2005-10-28

Similar Documents

Publication Publication Date Title
BR0008447A (pt) Métodos de tratamento de distúrbios mitocondriais
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NZ522326A (en) Adenosine A2A receptor antagonists
CY1112560T1 (el) Πνευμονικη μεταφορα των αμινογλυκοσιδων
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
WO2003094835A3 (en) Fgf variants and methods for use thereof
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
SI1446119T1 (sl) Sestavki, ki obsegajo ipratorij in ksilometazolin, za zdravljenje obicajnega prehlada
BRPI0417820A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóide
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
EP1426375A3 (en) Analgesic spiroindole derivatives
DOP2002000429A (es) Imidazotriazinas
BR0211450A (pt) Método terapêutico
BR9809951A (pt) Método para tratamento da obesidade
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
YU20104A (sh) Postupci lečenja plućnih oboljenja
MXPA03009185A (es) Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson.
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BR0213037A (pt) Derivados de pirimidina
MXPA04002389A (es) Combinacion de un antagonista del receptor de adenosian a2a y un antidepresivo o ansiolitico.
SE9900834D0 (sv) Novel combination

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/52, A61K 31/522, A61K 45/00, A61P 11/00, A61P 9/12, C07D 473/06

Ipc: A61K 31/52 (2011.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2166 DE 10/07/2012.